Bristol Myers Squibb (BMS) is to acquire cell therapy developer 2seventy bio for approximately $286 million. Under the terms of the agreement, BMS will commence a tender offer to acquire all outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction. 2seventy bio’s Board of Directors have unanimously recommended […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!